Predictive factors for pericardial effusion identified by heart dose-volume histogram analysis in oesophageal cancer patients treated with chemoradiotherapy

被引:18
|
作者
Hayashi, K. [1 ]
Fujiwara, Y. [2 ]
Nomura, M. [1 ]
Kamata, M. [1 ]
Kojima, H. [1 ]
Kohzai, M. [1 ]
Sumita, K. [1 ]
Tanigawa, N. [1 ]
机构
[1] Kansai Med Univ, Dept Radiol, Hirakata, Osaka, Japan
[2] Kinki Univ, Sch Med, Nara Hosp, Dept Digest Surg, Nara, Japan
来源
BRITISH JOURNAL OF RADIOLOGY | 2015年 / 88卷 / 1046期
关键词
SQUAMOUS-CELL CARCINOMA; DEFINITIVE CHEMORADIOTHERAPY; PHASE-II; TRIAL; RADIOTHERAPY; TOXICITY; 5-FLUOROURACIL; CISPLATIN; THERAPY;
D O I
10.1259/bjr.20140168
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: To identify predictive factors for the development of pericardial effusion (PCE) in patients with oesophageal cancer treated with chemotherapy and radiotherapy (RT). Methods: From March 2006 to November 2012, patients with oesophageal cancer treated with chemoradiotherapy (CRT) using the following criteria were evaluated: radiation dose >50 Gy; heart included in the radiation field; dose-volume histogram (DVH) data available for analysis; no previous thoracic surgery; and no PCE before treatment. The diagnosis of PCE was independently determined by two radiologists. Clinical factors, the percentage of heart volume receiving >5-60Gy in increments of 5Gy (V5-60, respectively), maximum heart dose and mean heart dose were analysed. Results: A total of 143 patients with oesophageal cancer were reviewed retrospectively. The median follow-up by CT was 15 months (range, 2.1-72.6 months) after RT. PCE developed in 55 patients (38.5%) after RT, and the median time to develop PCE was 3.5 months (range, 0.2-9.9 months). On univariate analysis, DVH parameters except for V60 were significantly associated with the development of PCE (p < 0.001). No clinical factor was significantly related to the development of PCE. Recursive partitioning analysis including all DVH parameters as variables showed a V10 cut-off value of 72.8% to be the most influential factor. Conclusion: The present results showed that DVH parameters are strong independent predictive factors for the development of PCE in patients with oesophageal cancer treated with CRT. Advances in knowledge: A heart dosage was associated with the development of PCE with radiation and without prophylactic nodal irradiation.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Predictive value of dose-volume histogram parameters for pericardial effusion after concurrent chemoradiotherapy for esophageal cancer
    Ito, Y
    Ishikura, S
    Hirota, S
    Soejima, T
    Tsujino, K
    Yoden, E
    Okamoto, Y
    Nihei, K
    Onozawa, M
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S420 - S420
  • [2] Dose-volume histogram parameters and clinical factors associated with pleural effusion in esophageal cancer patients after treated with chemoradiotherapy
    Shirai, K.
    Kitamoto, Y.
    Satoh, Y.
    Higuchi, K.
    Tamaki, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S257 - S257
  • [3] A dose-volume histogram analysis of the PTV in patients with advanced head and neck cancer treated with concomitant chemoradiotherapy
    Georqe, L.
    Cazalet, M.
    Digue, L.
    Cowen, D.
    Paris, J.
    Bagarry-Liegey, D.
    Giovanni, A.
    Zanaret, M.
    Pignon, T.
    EJC SUPPLEMENTS, 2005, 3 (02): : 296 - 296
  • [4] A dose-volume histogram analysis of the PTV in patients with advanced head and neck cancer treated with concomitant chemoradiotherapy.
    Gross, E.
    George, L.
    Cowen, D.
    Cazalet, M.
    Pignon, T.
    RADIOTHERAPY AND ONCOLOGY, 2007, 82 : S44 - S44
  • [5] Comparison of adverse effects of proton and X-ray chemoradiotherapy for oesophageal cancer using an adaptive dose-volume histogram analysis
    Makishima, H.
    Ishikawa, H.
    Terunuma, T.
    Hashimoto, T.
    Yamanashi, K.
    Sekiguchi, T.
    Mizumoto, M.
    Okumura, T.
    Tsuboi, K.
    Sakurai, H.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S576 - S576
  • [6] DOSE VOLUME HISTOGRAM PARAMETERS AND CLINICAL FACTORS ASSOCIATED WITH PLEURAL EFFUSION AFTER CHEMORADIOTHERAPY IN ESOPHAGEAL CANCER PATIENTS
    Shirai, Katsuyuki
    Tamaki, Yoshio
    Kitamoto, Yoshizumi
    Murata, Kazutoshi
    Satoh, Yumi
    Higuchi, Keiko
    Nonaka, Tetsuo
    Ishikawa, Hitoshi
    Katoh, Hiroyuki
    Takahashi, Takeo
    Nakano, Takashi
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (04): : 1002 - 1007
  • [7] Predictive value of pancreatic dose-volume metrics on sarcopenia rate in gastric cancer patients treated with adjuvant chemoradiotherapy
    Li, Yi
    Wang, Wen-bo
    Jiang, Huan-gang
    Dai, Jing
    Xia, Ling
    Chen, Ji
    Xie, Cong-hua
    Peng, Jin
    Liao, Zheng-kai
    Gao, Yan
    Zhou, Yun-feng
    Zhou, Fu-xiang
    CLINICAL NUTRITION, 2019, 38 (04) : 1713 - 1720
  • [8] Analysis of dose-volume histogram parameters for radiation pneumonitis after concurrent chemoradiotherapy for esophageal cancer
    Asakura, H.
    Hashimoto, T.
    Zenda, S.
    Harada, H.
    Hirakawa, K.
    Mizumoto, M.
    Yamashita, H.
    Fuji, H.
    Murayama, S.
    Nishimura, T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S302 - S302
  • [9] Cardiac toxicities after concurrent chemoradiotherapy for esophageal cancer - Dose-volume histogram (DVH) analysis
    Hashimoto, T.
    Asakura, H.
    Zenda, S.
    Hashii, H.
    Mizumoto, M.
    Harada, H.
    Furutani, K.
    Fuji, H.
    Murayama, S.
    Nishimura, T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S130 - S130
  • [10] Dose-volume histogram analysis as predictor of radiation pneumonitis in primary lung cancer patients treated with radiotherapy
    Fay, M
    Tan, A
    Fisher, R
    Mac Manus, M
    Wirth, A
    Ball, D
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 61 (05): : 1355 - 1363